Results 71 to 80 of about 44,894 (310)

An increase in urinary primaquine and a reduction in urinary primaquine-5,6-orthoquinone in the Thai population with CYP2D6 reduced enzyme function

Heliyon
Objectives: Primaquine is metabolized by the cytochrome P450-2D6 enzyme (CYP2D6) to an active primaquine-5,6-orthoquinone (POQ). No relationships of CYP2D6 polymorphisms with the pharmacokinetics of primaquine and POQ were reported in the Thai population.
Waritda Pookmanee, Siriwan Thongthip, Mathirut Mungthin, Chonlaphat Sukasem, Jeeranut Tankanitlert, Pajaree Chariyavilaskul, Supeecha Wittayalertpanya   +6 more
doaj   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

Clinical pharmacology and therapy, 2015
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety.
J. K. Hicks, J. Bishop, K. Sangkuhl, Daniel J. Müller, Yuan Ji, S. Leckband, J. S. Leeder, Rebecca L. Graham, Dana L. Chiulli, A. Llerena, T. Skaar, S. Scott, J. Stingl, T. E. Klein, K. Caudle, A. Gaedigk   +15 more
semanticscholar   +1 more source

CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis.

British Journal of Clinical Pharmacology, 2020
CYP2D6 genetic polymorphisms are associated with metoprolol pharmacokinetics. Whether the clinical response to metoprolol is also affected remains uncertain. METHODS We conducted a systematic review on the effects of CYP2D6 polymorphism on the clinical
Maxime Meloche, Michael Khazaka, Imad Kassem, A. Barhdadi, Marie-Pierre Dubé, Simon de Denus   +5 more
semanticscholar   +1 more source

In vitro comparative analysis of metabolic capabilities and inhibitory profiles of selected CYP2D6 alleles on tramadol metabolism

Clinical and Translational Science
Tramadol, the 41st most prescribed drug in the United States in 2021 is a prodrug activated by CYP2D6, which is highly polymorphic. Previous studies showed enzyme‐inhibitor affinity varied between different CYP2D6 allelic variants with dextromethorphan ...
Noor Ahmed Nahid, Siva Rama Raju Kanumuri, Abhisheak Sharma, Danxin Wang, Julie A. Johnson   +4 more
doaj   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

Clinical pharmacology and therapy, 2018
Tamoxifen is biotransformed by CYP2D6 to 4‐hydroxytamoxifen and 4‐hydroxy N‐desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong
Matthew P. Goetz, K. Sangkuhl, H. Guchelaar, M. Schwab, M. Province, M. Whirl-Carrillo, W. Symmans, Howard L. McLeod, Mark J. Ratain, Hitoshi Zembutsu, A. Gaedigk, R. V. van Schaik, James N. Ingle, Kelly E. Caudle, T. Klein   +14 more
semanticscholar   +1 more source

Transfer learning enables prediction of CYP2D6 haplotype function

PLoS Comput. Biol., 2020
Cytochrome P450 2D6 (CYP2D6) is a highly polymorphic gene whose protein product metabolizes more than 20% of clinically used drugs. Genetic variations in CYP2D6 are responsible for interindividual heterogeneity in drug response that can lead to drug ...
G. McInnes, R. Dalton, K. Sangkuhl, M. Whirl-Carrillo, Seung‐been Lee, P. Tsao, A. Gaedigk, R. Altman, E. Woodahl   +8 more
semanticscholar   +1 more source

Novel Structure of the CYP2D6 Gene that Confuses Genotyping for the CYP2D6*5 Allele

Drug Metabolism and Pharmacokinetics, 2005
We encountered DNA samples which showed a positive product using a long PCR-based method for the detection of CYP2D6*5, indicating deletion of the entire CYP2D6 gene, but the samples did not show a band related to CYP2D6*5 in either XbaI- or EcoRI-RFLP analysis. To achieve genotyping with accuracy, we performed a further genetic analysis to clarify the
FUKUDA, Tsuyoshi, MAUNE, Hiromi, IKENAGA, Yuka, NAOHARA, Masakazu, FUKUDA, Kazuhiro, AZUMA, Junichi   +5 more
openaire   +2 more sources

Spectroscopic and In Silico Determination of the Structural and Antioxidant Properties of Essential Oils From Lavandula Species Cultivated in the Silivri Region of Istanbul

Journal of the American Oil Chemists' Society, EarlyView.
ABSTRACT Plants are important sources of bioactive compounds that contribute to nutrition, health maintenance, and disease prevention. In this study, the chemical composition and antioxidant potential of essential oils obtained from Lavandula angustifolia “Sevtopolis” and Lavandula × intermedia cultivated in the Silivri region of Istanbul were ...
Bilge Bicak, Beray Kizilkaya, Serda Kecel Gunduz, Aliye Demet Demirag, Sabriye Percin Ozkorucuklu   +4 more
wiley   +1 more source

Effect of CYP2D6 and ABCB1 polymorphisms on pharmacokinetics and efficacy of aripiprazole in pediatric tic disorders

BMC Pediatrics
Background Aripiprazole (ARI) is the first-line treatment for tic disorders (TD). Cytochrome P450(CYP)2D6 (CYP2D6) and ATP-binding cassette, sub-family B, member 1 (ABCB1) transporter are involved in the metabolism of ARI.
Yingying Xin, Liuliu Gao, Sichan Li, Jun Wang, Chen Chen, Yali Tuo, Gang Nie, Ruizhen Li, Dan Sun, Yongli Fu, Yang Wang, Zhisheng Liu   +11 more
doaj   +1 more source

Does Next Generation Sequencing (NGS)-Based CYP2D6 Sequencing Improve Genotype-Phenotype Concordance in Tamoxifen-Treated Patients? [PDF]

Clin Pharmacol Ther
CYP2D6 metabolizes about 20% of commonly used drugs, including tamoxifen, a major hormone therapy for breast cancer. Although the relationship between tamoxifen pharmacokinetics and CYP2D6 genotype has been demonstrated, residual variability in drug exposure remains unexplained.
Petit J, Plenecassagnes J, Brice A, Dalenc F, Mallet L, Chatelut E, Al Saati A, Thomas F.   +7 more
europepmc   +2 more sources